Targeting excitatory/inhibitory neurotransmission by wogonin: integrated In Silico and In Vivo evidence in Parkinson’s disease model

Shivani Chib; Bhaskar Jyoti Dutta; Randhir Singh

doi:10.1080/17582024.2026.2669596

May 7, 2026Neurodegenerative Disease Management

Targeting excitatory/inhibitory neurotransmission by wogonin: integrated In Silico and In Vivo evidence in Parkinson’s disease model

View at Publisher

Ask AI

Bookmark

Share

Key Points

This study aims to explore the neuroprotective effects of wogonin on neurotransmission in a Parkinson’s disease model.
Assessed neurochemical levels using chemical assays and ELISA for key biomarkers.
Performed Western blotting for GABA-A, gephyrin, MAO-B, and α-synuclein.
Evaluated tyrosine hydroxylase expression and neuronal integrity histologically.
Wogonin reduced levels of oxidative stress markers, IL-6, caspase-3/9, and enhanced preservation of dopamine and TH expression.
Demonstrated dose-dependent protection of striatal histoarchitecture.
Modulated E/I neurotransmission markers, indicating protective neurobehavioral effects.

Implication

Investigates wogonin’s effects on neuroprotection in a Parkinson’s disease model, suggesting a multitarget approach.

Abstract

AIM: The present study aimed to investigate neuroprotective potential of wogonin in rotenone-induced PD, with particular focus on modulation of excitatory/inhibitory (E/I) neurotransmission and other pathological factors, including oxidative stress, neuroinflammation, and apoptosis. METHODS: levels were measured using chemical assays. IL-6, caspase-3/9, parvalbumin, and c-FOS were quantified by ELISA and dopamine levels by HPLC-ECD. Western blotting was performed for GABA-A, gephyrin, MAO-B, and α-synuclein, while tyrosine hydroxylase (TH) expression and neuronal integrity were evaluated histologically. Wogonin dose-dependently attenuated these changes and preserved striatal histoarchitecture. CONCLUSION: Wogonin modulated the markers related to E/I neurotransmission and exhibited neuroprotection, highlighting its multitarget therapeutic potential in PD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chib et al. (2026) studied this question.

synapsesocial.com/papers/69fecf94b9154b0b828767c6 https://doi.org/10.1080/17582024.2026.2669596

View at Publisher

Ask AI

Bookmark

Share

Targeting excitatory/inhibitory neurotransmission by wogonin: integrated In Silico and In Vivo evidence in Parkinson’s disease model

Key Points

Implication

Abstract

Discussion

Cite This Study

Targeting excitatory/inhibitory neurotransmission by wogonin: integrated In Silico and In Vivo evidence in Parkinson’s disease model

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading